Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) EPS (Weighted Average and Diluted) (2020 - 2025)

Historic EPS (Weighted Average and Diluted) for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to -$0.3.

  • Tarsus Pharmaceuticals' EPS (Weighted Average and Diluted) rose 5081.97% to -$0.3 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.01, marking a year-over-year increase of 4668.44%. This contributed to the annual value of -$3.07 for FY2024, which is 3348.76% up from last year.
  • Tarsus Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to -$0.3 in Q3 2025, which was up 5081.97% from -$0.48 recorded in Q2 2025.
  • Tarsus Pharmaceuticals' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.47 during Q1 2021, with a 5-year trough of -$1.28 in Q3 2023.
  • For the 5-year period, Tarsus Pharmaceuticals' EPS (Weighted Average and Diluted) averaged around -$0.65, with its median value being -$0.7 (2021).
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' EPS (Weighted Average and Diluted) surged by 16351.35% in 2021, and later plummeted by 38750.0% in 2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.7 in 2021, then surged by 30.49% to -$0.49 in 2022, then crashed by 159.18% to -$1.27 in 2023, then soared by 51.66% to -$0.61 in 2024, then soared by 51.13% to -$0.3 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$0.3 in Q3 2025, compared to -$0.48 in Q2 2025 and -$0.64 in Q1 2025.